Dr. Bernhard Kirschbaum, Chairman
Bernhard Kirschbaum, PhD studied and researched in biochemistry and physiological chemistry at the University of Konstanz (Germany), receiving his PhD in 1989. He moved on to work at the Rockefeller University (New Yortk) and the Pasteur Institute (Paris). Subsequently, he joined the pharmaceutical industry where he covered a broad range of technological and disease areas. Before his retirement as executive Bernhard Kirschbaum was head of Global Research and Early Development at Merck Serono. In this role he was a member of the Pharmaceutical Executive Committee. Prior to joining Merck KGaA in 2005 he was Vice President Discovery Research, Global Head of Therapeutic Domains “Thrombosis & Angiogenesis” for Sanofi-Aventis. He also worked for Aventis, Hoechst Marion Roussel in various senior positions and headed the Centre of Applied Genomics in Martinsried. Bernhard Kirschbaum is currently member of several biotech company boards.
Dr. Christian Schneider
Head of Treasury Vice President SMS GmbH
Dr. Martin Pfister
Senior Investment Manager HighTech Gründerfonds
Dr. Gaston Matthyssens
Dr. Wolf-Hagen Schunck
Max-Delbrück-Center for Molecular Medicine (MDC)
Dr. Schunck represents the group of scientific founders in the Board of Directors of OMEICOS. He is a biochemist at the Max Delbrueck Center for Molecular Medicine in Berlin-Buch and has over 30 years of research experience in the field of cytochrome P450 (CYP) enzymes.
In the late 1990s, Dr. Schunck’s laboratory started to investigate mammalian CYP enzymes involved in the formation of bioactive lipid mediators derived from omega-6 and omega-3 polyunsaturated fatty acids (PUFAs). Collaborating with cardiologists and nephrologists, he became interested in the role of CYP-eicosanoids as mediators of intrinsic mechanisms protecting against cardiac and renal injury. Searching for metabolites mediating the cardioprotective effects of omega-3 PUFAs, Dr. Schunck’s laboratory identified 17,18-epoxyeicosatetraenoic acid (17,18-EEQ) as the most promising candidate and developed together with Dr. John R. Falck from the UTSW in Dallas robust synthetic analogues for in vivo administration.
From 2010 to 2013, Dr. Schunck supervised the MDC-granted PreGoBio-project on the development of novel eicosanoid-like antiarrhythmic drugs that provided the scientific basis for the foundation of OMEICOS.
The research of Dr. Schunck yielded 98 publications, the title of which can be retrieved from Pubmed: http://www.ncbi.nlm.nih.gov/pubmed/?term=schunck-wh.
The current work of Dr. Schunck is focused on dissecting the cellular and molecular mechanisms underlying the unique biological properties of 17,18-EEQ and developing new fields of clinical application in collaboration with academic partners and OMEICOS.